An update from Filament Health Corp. ( (TSE:FH) ) is now available.
Filament Health Corp. has received FDA authorization for a phase 2 clinical trial of its botanical psilocybin drug candidate, PEX010, aimed at treating opioid use disorder (OUD). The trial, sponsored by the University of Pennsylvania and funded by Wellcome Leap, will explore the effects of psychedelic-assisted psychotherapy on neurocognitive, behavioral, and clinical outcomes in OUD patients. This initiative marks a significant step in addressing the opioid crisis, with PEX010 previously showing promise in treating alcohol use disorder. The trial is expected to commence by Q3 2025, highlighting Filament’s role in advancing psychedelic research and its potential impact on addiction treatment.
More about Filament Health Corp.
Filament Health Corp. is a clinical-stage natural psychedelic drug development company focused on creating safe, standardized, naturally-derived psychedelic medicines. The company aims to improve lives by making these medicines accessible to those in need through its proprietary intellectual property platform, which supports the discovery, development, and delivery of natural psychedelic medicines for clinical development.
Technical Sentiment Signal: Strong Buy
For an in-depth examination of FH stock, go to TipRanks’ Stock Analysis page.